From the Editor-in-Chief: Oncology in the Time of "Moore's Law"
April 16th 2019In an article published in Electronics Magazine on April 9, 1965, Intel cofounder Gordon Earle Moore noted that the number of transistors in an integrated circuit doubled every year. He extrapolated that this rate of growth in computing power would continue to double every 2 years throughout the late 1960s and in to the 1970s and 1980s. The prediction, which became known as Moore’s Law, proved prescient. Intel and other industry leaders took this as both a prediction for the pace of innovation and a push for the industry to create “computing [that] would dramatically increase in power, and decrease in relative cost, at an exponential pace.” From 1965 to today, the technologies, depth of innovation, and corresponding impact from discoveries made in the pursuit of achieving and sustaining Moore’s vision have affected our lives in profound and unexpected days. Conversations rarely take place today without someone glancing at a smartphone to close a business deal, to let family know they will be late, or to post pictures of the conversation on a social media site.
Read More
From the Editor-In-Chief: Getting to The Prestige in Cancer Care
October 19th 2018“Every great magic trick consists of three parts or acts. The first part is called ‘The Pledge.’ The magician shows you something ordinary. ...The second act is called ‘The Turn.’ The magician takes the ordinary something and makes it do something extraordinary. Now you’re looking for the secret, but you won’t find it, because of course you’re not really looking...Every magic trick has a third act, the hardest part, the part we call ‘The Prestige.’” — Christopher Priest, The Prestige
Read More
Halt and Catch Fire: Can the Digital Revolution Empower the Move Toward Value-Based Cancer Care?
December 13th 2017There is no shortage of academic, industry, and government sources that identify value as equaling cost/outcomes; there is far less uniformity of opinion when it comes to defining what that means for a particular patient affected by cancer.
Read More
From "Magic Bullets" to Precision Medicine—Ensuring More Patient-Centered Cancer Care
August 10th 2017As we shift to the precision-medicine model of cancer care, it is essential to develop a scalable system that can deliver these care solutions in a patient-centered, economically sustainable way.
Read More
Transparency and Collaboration Key to the Success of Value-Based Payment Models
April 20th 2017As the task of describing value delivery in cancer care seems to grow in complexity the closer that we examine it, this is essential in order to both rationally control the growth of healthcare costs and ensure that we do not undermine patient care.
Read More
Interesting Times in Healthcare
December 8th 2016These are uncertain times in healthcare and the anxiety levels of stakeholders remain high as everyone waits to see how the appointments and policy changes within the new administration will impact healthcare in the United States in the near future.
Read More
Surmounting the Quality Chasm in Healthcare
June 20th 2016Despite the breadth of metrics, there seems to be a significant disconnect between the relatively prosaic, process-based measures that largely dominate our quality portfolio and the high-level, aspiration-driven demands of delivering increasingly complex care to patients with cancer.
Read More
So Many Metrics, Yet So Little Known About Quality and Value in Cancer Care
June 9th 2016As cancer care stakeholders move through processes of creating, deploying, and reporting quality metrics, it is important to remember that these measures alone are not sufficient to bring better care to patients.
Read More
Clinical Pathways: A Systems Approach Toward More Patient-Centric Cancer Care Delivery
April 16th 2016Despite the fundamental advances in cancer care technology and care delivery that have made these improvements possible, our delivery system remains quite inefficient and frequently falls short of being truly patient-centered. Is a system-based solution the answer?
Read More
Shaping the Future of Immuno-Oncology
February 11th 2016While the number and diversity of immunologically-based anticancer agents have increased dramatically, a number of challenging questions persist: sequencing with existing regimens, selection of best responders, cost, and patient access.
Read More
The Struggle Between Oncology Care Cost and Value
December 15th 2015While cost is an important component of value, it tells only a small part of the cancer care story. By focusing on issues of payment and cost alone, we miss our opportunity to engage cancer care stakeholders in the process of creating a more effective system of care.
Read More